Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
prnewswire.com
news
2022-10-18 12:00:00

Charles River will manufacture both plasmid DNA and viral vectors for late phase clinical trials targeting degenerative ocular diseases with no known cure
WILMINGTON, Mass. and DALLAS, Oct. 18, 2022 /PRNewswire/ -- Charles River Laboratories International, Inc. and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced a comprehensive manufacturing collaboration utilizing Charles River's extensive contract development and manufacturing (CDMO) services in both plasmid DNA and viral vectors.
